Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

KENILWORTH, N.J.& MIAMI--(BUSINESS WIRE) September 1, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the initiation of the Phase 3 MOVe-AHEAD clinical trial to evaluate...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials